Boston lawsuit claims DES-breast cancer link
Fifty-three women from around the country are suing drug companies, including Eli Lilly and Co., who made and promoted DES for millions of pregnant women from about 1938 to the early 1970s.
Health Care & Life Sciences
Articles
Healthx receives $22M capital infusion
Frontier Capital in Charlotte, N.C., provided the funding that will support the continued expansion of Healthx, a local provider of online health care portals.
National life sciences law firm opens office here
New York-based Epstein Becker Green already has clients here, including Biomet and Roche Diagnostics.
Lilly challenging Biogen patent in London lawsuit
Eli Lilly and Co. has sued Biogen Idec Inc. in a London court to revoke a European patent on a potential treatment for immune-system diseases.
WellPoint, other insurers profit from health law they oppose
Insurance companies spent millions of dollars trying to defeat the U.S. health-care overhaul. But profit margins at the companies have widened to levels not seen since before the recession, a Bloomberg Government study shows.
Lilly’s 2012 earnings forecast misses analyst estimates
Indianapolis-based Eli Lilly and Co. provided a 2012 earnings forecast Thursday morning that missed analyst estimates by a wide margin, sending shares down.
IU doc growth slower than expected
Indiana University Health Physicians started as the Indiana Clinic three years ago with plans to employ at least 1,200 physicians by now. That hasn’t happened, but the organization said it won’t stop folding doctors into its organization.
Shareholders gives earful to BASI execs
For the first time in three years, Bioanalytical Systems Inc. boosted its annual revenue. But instead of receiving congratulations, one of the company’s largest shareholders said the company’s trends are “bleak.”
Walgreen expects to lose most Express Scripts biz
Drugstore operator Walgreen Co. said Thursday it expects to lose almost 90 percent of prescriptions handled by pharmacy benefits manager Express Scripts Inc. after it leaves Express Scripts' networks on Jan. 1.
Lilly losing dominance in diabetes treatment
Eli Lilly and Co., after more than a decade of setbacks, is counting on diabetes to help it survive a string of patent losses on other products that have begun to sap the drugmaker’s sales.
Endocyte stays course despite being battered by investors
After spending most of 2011 as a Wall Street darling, the year ended ugly for Endocyte Inc. But CEO Ron Ellis thinks the West Lafayette-based drug developer is in better position than ever.
WellPoint prevails in shareholder suit over 2001 restructuring
A federal judge has dismissed a shareholder class-action lawsuit against WellPoint stemming from the company’s 2001 conversion from a mutual insurer to a publicly traded company.
Filing: Roche considered leaving Indy
It’s hard to believe now, but as recently as two years ago, Indianapolis was close to losing its 15th-largest employer. Roche Diagnostics Corp. was looking seriously at moving its 2,900-employee North American headquarters out of Indianapolis.
Q&A
Dr. Bryan Schneider, a professor at the Indiana University School of Medicine, led a team of researchers in identifying genetic variations that dispose some breast cancer patients to neuropathy when they are receiving chemotherapy with the drug Taxol. Schneider’s research was named one of the biggest advances in cancer research this year by the American Society of Clinical Oncology. The society’s foundation also gave Schneider a three-year, $450,000 grant to further the research.
Arcadia agrees to sell DailyMed to Walgreen
It looks like Arcadia Resources Inc.’s DailyMed pharmacy business will live on—but under the wing of Walgreen Co. instead of on its own.
YMCA revamps fundraising strategy for Pike Township
YMCA of Greater Indianapolis officials have started a $40 million fundraising campaign that will be used to fund three more local locations, including a much-delayed $10 million facility in Pike Township.
Fieldhouse gets Bankers Life name
It will be difficult to rebrand the arena where the Indiana Pacers play, but team officials praised sponsor CNO Financial for sticking with the $20 million naming-rights deal despite tough times.
Ex-Dow Agro scientist receives seven years for economic espionage
Kexue Huang was sentenced after pleading guilty in October to sending Dow AgroSciences trade secrets to China and Germany.
Ex-Dow Agro scientist set to be sentenced in espionage case
Federal prosecutors are recommending that Kexue Huang be sentenced to 87 months in prison for sending trade secrets worth millions to China and Germany.
Lilly enters drug-development deal with Immunogen
Cancer treatment developer Immunogen Inc. said Tuesday it will receive $20 million from Eli Lilly and Co. and could earn about $200 million in milestone payments under a collaboration agreement with the Indianapolis drugmaker.